Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Coastal Research Associates LLC

Neither a doctor nor a teaching hospital

Research payments

$821,881

181 payments

Through program year 2025, Coastal Research Associates LLC is reported as receiving $821,881 in research payments, across 181 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $152,673 19
2024 Research $23,479 11
2023 Research $125,462 14
2022 Research $93,397 13
2021 Research $197,362 28
2020 Research $86,179 54
2019 Research $143,328 42

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $393,367 124 payments
  2. AbbVie, Inc. $214,342 42 payments
  3. Ocular Therapeutix, Inc. $128,028 4 payments
  4. Sight Sciences, Inc. $57,916 8 payments
  5. Amneal Pharmaceuticals LLC $28,228 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Evaluation of the 24-Hour IOP-lowering Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension $124,021 12 payments
  2. A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma $91,149 6 payments
  3. A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $72,099 34 payments
  4. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $69,005 2 payments
  5. AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension $61,536 18 payments
  6. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $53,270 11 payments
  7. A prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy and safety of OTX-TIC (travoprost) intracameral implant in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) $51,482 1 payment
  8. The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $43,280 9 payments
  9. An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $40,277 27 payments
  10. Bimatoprost $28,228 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record